

A.- Creación de una Nueva Política Pública para la Introducción de la Vacuna Contra el Dengue en México, Secretaria de Salud, Primera Edición Enero 2014.

Juan López Mercedes, Secretaria de Salud, Kuri Morales Pablo Antonio, Subsecretario de Prevención y Promoción de la Salud, Velazco González Marcela, Subsecretaria de Administración y Finanzas.

B.- Introducing a Dengue Vaccine to Mexico: Development of a System for Evidence-Based Public Policy Recommendations

Betancourt Cravioto Miguel, Kuri Morales Pablo, González Roldán Jesús Felipe, Tapia Conyer Roberto, The Mexican Dengue Expert Group. PLOS Neglected Tropical Diseases 8 (7): 1-6. Betancourt Cravioto July 2014.

C.- Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America

Villar Luis, Horacio Dayan Gustavo, Arredondo García José Luis, Rivera Doris Maribel, Cuha Rivaldo, Deseda Carmen, Reynales Humberto, Costa Maria Selma, Morales Ramírez Javier Osvaldo, Carrasquilla Rey Luis Carlos, Dietze Reynaldo, Luz Kleber, Rivas Enrique, Miranda Montoya María Consuelo, Cortés Supelano, Zambrano Betzana, Langevin Edith, Boaz Mark, Tornieporth Nadia, Saville Melanie, Noriega Fernando. The New England Journal of Medicine (2015) 372:2, 113-123 Massachusetts Medical Society January 2015.

D.- Site-specific characterization of envelope protein N glycosylation on Sanofi Pasteur's tetravalent CYD dengue vaccine

Dubayle Jean, Vialle Sandrine, Schnaider Diane, Pontvianne Jérémy, Mantel Nathalie, Adam Olivier, Guy Bruno, Talaga Philippe. Published Online 3 February 2015. www.elsevier.com/locate/vaccine

E.- Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia. Vaccines (2015).

Dorigatti Ilaria, Aguas Ricardo, Donnelly Christl A., Guy Bruno, Coudeville Laurent, Jackson Nicholas, Saville Melanie, Ferguson Neil M. Published Online May 22, 2015 <http://dx.doi.org/10.1016/j.vaccine.2015.05.059>

F.- Tetravalent Dengue Vaccine for Children

Villar L, Dayan GH, Arredondo García J, Rivera DM, Cunha R, Deseda C, *et al.* Indian Pediatrics (2015) 1 (52): 237-240. March 15, 2015.

G.- Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.

Capeding Maria Rosario, Huu Tran Ngoc, S Hadinegoro Sri Rezeki, HJ Muhammad Ismail Hussain Imam, Chotpitayasunondh Tawee, Noreen Chua Mary, Quang Luong Chan, Rusmil Kusnandi, Nyoman Wirawan Dewa, Nallusamy Revathy, Pitisuttithum Puneet, Thisyakorn Usa, Yoon In-Kyu, van der Vliet Diane, Langevin Edith, Laot Thelma Hutagalung, Yaneet, Frago Carina, Boaz Mark, Wartel T Anh, Tornieporth Nadia G, Saville Melanie, Bouckennooghe Alain, and the CYD14 Study Group. Published Online July 11, 2014 [http://dx.doi.org/10.1016/S0140-6736\(14\)61060-6](http://dx.doi.org/10.1016/S0140-6736(14)61060-6)

H.- Efficacy of tetravalent dengue vaccine in Thai schoolchildren

Mckibben Linda, Moi Ling Meng, Takasaki Tomohiko, Kurane Ichiro, Sabchareon Arunee, Wallace Derek, Lang Jean, Bouckennooghe Alain, Moureau Annick, Tozan Yesim, John Albrecht, Müller Olaf. Vol 381 March 30, 2013, www.thelancet.com

I.- Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: A meta-analysis of randomized trials.

Da Costa Vivaldo G., Marques-Silva Ariany C., Floriano Vitor G., Moreli Marcos L. Published Online 19 July 2014. www.elsevier.com/locate/vaccine

J.- Symptomatic Versus Inapparent Outcome in Repeat Dengue Virus Infections is Influenced by the Time Interval between Infections and Study Year

Montoya Magda, Gresh Lionel, Mercado Juan Carlos, Williams Katherine L., Vargas Maria José, Gutiérrez Gamaliel, Kuan Guillermina, Gordon Aubree, Balmaseda Angel, Harris Eva. Published 8 August 2013. <http://10.1371/journal.pntd.0002357>

K.- Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: A randomized, placebo-controlled. Phase III study.

HSS Amar-Singh, Koh Mia-Tuang, Tan Kee Kah, Chan Lee Gaik, Zhou Lynn, Bouckennooghe Alain, Crevat Denis, Hutagalung Yanee. Published Online 14 October 2013. www.elsevier.com/locate/vaccine

L.- Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

Sabchareon Arunee, Wallace Derek, Sirivichayakul Chukiat, Limkittikul Kriengsak, Chanthavanich Pornthep, Suvannadabba Saravudh, Jiwariyavej Vithaya, Dulyachai Wut, Pengsaa Krisana, Wartel T Anh, Moureau Annick, Saville Melanie, Bouckennooghe Alain, Viviani Simonetta, Tornieporth Nadia G., Lang Jean. Published Online September 11, 2012 [http://dx.doi.org/10.1016/S0140-6736\(12\)61428-7](http://dx.doi.org/10.1016/S0140-6736(12)61428-7)

M.- Sanofi's Pasteur Dengue Vaccine Demonstrates Proof of Efficacy

Sanofi Pasteur's press release 25 July 2012. www.sanofispasteur.com

N.- From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

Guy Bruno, Barrere Beatrice, Malinowski Claire, Saville Melanie, Teyssou Remy, Lang Jean. Published Online 12 July 2011. www.elsevier.com/locate/vaccine

O.- The pathogenesis of dengue

Whitehorn Jamie, Simmons Cameron P. Published Online 21 July 2011. <http://10.1016/j.vaccine.2011.07.022>

P.- Controversies in dengue pathogenesis

Halstead Scott B. Paediatrics and International Child Health, 2012, Vo. 32, No. S1. Pp 5-9.

Q.- Determinants of Inapparent and Symptomatic Dengue Infection in a Perspective Study os Primary School Children in Kamphaeng Phet, Thailand

Endy TP, Anderson KB., Nisalak A., Yoon I-K, Green S, et al (2011). PloS Negl Trop Dis 5(3): e975. doi:10.1371/journal.pntd.0000975 March 2011 / volume 5 / issue 3 / e975 www.plosntds.org

R.- Severe dengue: questioning the paradigm

Murgue Bernadette. Institute Pasteur. Published Online 17 November 2009. www.elsevier.com/locate/micinf

S.- A Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Hemorrhagic Fever Model

Libraty Daniel H., Acosta Luz P. Tallo Veronica., Segubre-Mercado Edelwisa, Bautista Analisa, Potts James A., Jarman Richard G., Yoon In-Kyu, Gibbons Robert V., Brion Job D., Capeding Rosario Z. Plos Medicine October 2009. Volume 6/ Issue 10 / e1000171

T.- Guidelines for clinical trials of dengue vaccine in endemic areas

Hombach Joachim. Journal of Clinical Virology 46. S2 (2009) 57-59.

U.- Dengue Virus (DV) Enhancing Antibody Activity in Preillness Plasma Does Not Predict Subsequent Disease Severity or Viremia in Secondary DV Infection

Laoprasopwattana Kamolwish, Libraty Daniel H., Endy Timothy P., Nisalak Ananda, Chunsuttiwat Supamit, Vaughn David W., Reed George, Ennis Francis A., Rothman Alan L., and Green Sharon. JID, The Journal of Infectious Diseases. 2005; 192:510-9 Published Online 5 July 2005. Pp. 510-519.

V.- Preguntas y respuestas sobre las vacunas contra el dengue: estudio fase III de la vacuna CYD-TDV en América Latina, Organización Mundial de la Salud, OMS. Noviembre 2014,

http://www.who.int/immunization/research/development/ES_QA_dengue_vaccine_LatAm_nov14.pdf

W.- Development of Sanofi Pasteur tetravalent dengue vaccine

Lang Jean, Development of Sanofi Pasteur tetravalent dengue vaccine. Rev. Inst. Med. Trop. Sao Paulo, 54 (Suppl. 18), S15-S17, 2012.

X.- The New England Journal of Medicine Publishes Results of Final Landmark Phase III Efficacy Clinical Study of Sanofi Pasteur's Dengue Vaccine Candidate

Sanofi Pasteur's press release 3rd November 2014. www.sanofispasteur.com

Y.- Vacuna Candidata Líder contra el Dengue. Podría cambiar millones de Vidas, SANOFI PASTEUR, Julio 2014,

http://www.sanofipasteur.com/es/Documents/PDF/Factsheet_Dengue_SP_Commitment_2014_07_03_SP.pdf

Z.- Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded to Singapore and Vietnam

Sanofi Pasteur's press release 21 April 2009. www.sanofispasteur.com